tandutinib

Tandutinib is an orally administered, small molecule inhibitor of type III receptor tyrosine kinases, specifically targeting FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor receptor (PDGFR), and proto-oncogene protein c-KIT. It is a piperazinyl quinazoline derivative developed as an antineoplastic agent for the treatment of cancers such as acute myeloid leukemia (AML) and glioblastoma. By inhibiting the autophosphorylation of these kinases, tandutinib blocks downstream signaling pathways involved in cellular proliferation and survival, thereby inducing apoptosis in malignant cells. The drug was granted fast-track status by the FDA for AML but has not been approved for any indication. Clinical development included phase I/II trials in AML and glioblastoma; however, further development for glioblastoma was discontinued due to limited efficacy and toxicity concerns[1][2][3][4][7].

Other names

tandutinib387867-13-2